Mesoblast Limited (NASDAQ:MESO) Shares Sold by Summit X LLC

Summit X LLC trimmed its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,655 shares of the company’s stock after selling 2,039 shares during the period. Summit X LLC owned about 0.11% of Mesoblast worth $2,884,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Prosperity Wealth Management Inc. grew its holdings in Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock worth $1,846,000 after acquiring an additional 1,795 shares during the period. Lindbrook Capital LLC grew its holdings in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares during the period. Pine Valley Investments Ltd Liability Co grew its holdings in Mesoblast by 78.7% in the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 20,931 shares of the company’s stock valued at $414,000 after purchasing an additional 9,217 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Mesoblast in the fourth quarter valued at approximately $2,744,000. Finally, Sageworth Trust Co acquired a new stake in Mesoblast in the fourth quarter valued at approximately $198,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on MESO shares. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Trading Up 1.6 %

NASDAQ MESO opened at $13.28 on Wednesday. The stock’s 50 day simple moving average is $17.61 and its 200-day simple moving average is $12.51. Mesoblast Limited has a 1-year low of $2.05 and a 1-year high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.